A highly significant association between high JAK/STAT3 expression within tumor cells and reduced cancer-specific survival in patients with high stromal invasion (TSP high ) was identified across 3 independent CRC patient cohorts, including the TrasnSCOT clinical trial cohort.
← all excerpts
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
1
—
—